Displaying drugs 13476 - 13500 of 15155 in total
Niaouli oil
Experimental
Chamaecyparis obtusa whole
Experimental
Gastrodia elata whole
Experimental
Oxelumab
Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Investigational
Surzebiclimab
Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).
Investigational
Torudokimab
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Uliledlimab
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Efmitermant alfa
Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).
Investigational
Axalimogene filolisbac
Axalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
Investigational
Glutazumab
Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.
Investigational
Neihulizumab
Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.
Investigational
Inlezifigene civaparvovec
Experimental
Rovoctocogene durparvovec
Experimental
Cevaretigene ritoparvovec
Experimental
Bevufenogene nofeparvovec
Experimental
Isaralgagene civaparvovec
Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme. It is developed by Sangamo Therapeutics and investigated in Fabry Disease.
Investigational
Matched Description: … It is developed by Sangamo Therapeutics and investigated in Fabry Disease. …
Sesiclenegene cosaparvovec
Investigational
Peboctocogene camaparvovec
Investigational
Aguracingene cadoparvovec
Investigational
Laruparetigene zovaparvovec
Investigational
Lixmabegagene relduparvovec
Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). It is under development for the treatment of GM1 gangliosidosis.
Experimental
Zorevunersen
Investigational
ALMB-0168
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
Mitsugumin-53
Investigational
AMT-130
Investigational
Displaying drugs 13476 - 13500 of 15155 in total